Walter and Eliza Hall Institute of Medical Research
Welcome,         Profile    Billing    Logout  
 13 Trials 
39 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
DiMeglio, Linda A
INHALE-1, NCT04974528: Afrezza® Study in Pediatrics

Active, not recruiting
3
319
US
Afrezza, Technosphere Insulin, Rapid-acting Insulin Analog, insulin aspart, insulin lispro, insulin glulisine, Novolog®, Fiasp®, Humalog®, Admelog®, Apidra®, Basal Insulin, insulin glargine, insulin degludec, insulin detemir, Lantus®, Abasaglar®, Basaglar®, Semglee®, Toujeo®, Tresiba®, Levemir®
Mannkind Corporation, Jaeb Center for Health Research
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
10/24
05/25
NCT05378672: A Study to Inv. Safety, Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children <6 Years With T1D

Recruiting
3
8
US
Dasiglucagon, Zegalogue, ZP4207
Zealand Pharma, Novo Nordisk A/S
Hypoglycemia, Type 1 Diabetes
09/24
09/24
NCT03929601: Rituximab-pvvr and Abatacept Vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes

Recruiting
2
74
US, RoW
Rituximab-pvvr, Ruxience, Abatacept, Orencia, Sterile Sodium Chloride, 0.9% Sodium Chloride Water for Injection
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH)
Type 1 Diabetes Mellitus
10/27
10/29
TADPOL, NCT05594563: TArgeting Type 1 Diabetes Using POLyamines

Recruiting
2
70
US
DFMO, Difluoromethylornithine, Placebo
Emily K. Sims, Juvenile Diabetes Research Foundation, Cancer Prevention Pharmaceuticals, Inc.
Type 1 Diabetes
12/27
12/27
TN28, NCT04291703: STOP-T1D Low-Dose (ATG)

Active, not recruiting
2
101
US, RoW
Antithymocyte Globulin, Thymoglobulin, Placebo (for ATG)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Diabetes Mellitus, Type 1
12/28
12/29
RescuiNGkids, NCT04992312 / 2021-006088-61: A Study of Nasal Glucagon (LY900018) in Pediatric Participants With Type 1 Diabetes

Completed
1
7
US
Glucagon Nasal Powder [Baqsimi], LY900018, Baqsimi
Eli Lilly and Company, Eli Lilly and Company
Type 1 Diabetes
11/23
11/23
TOPPLE T1D, NCT04279613: A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041

Completed
1
47
US
NNC0361-0041, Placebo
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Novo Nordisk A/S
Type I Diabetes
08/23
04/24
NCT05403502: Safety Evaluation of an Advanced Hybrid Closed Loop System Using Lyumjev With the Tandem t:Slim X2 Insulin Pump With Control-IQ Technology in Adults, Adolescents and Children With Type 1 Diabetes

Completed
N/A
183
US
t:slim X2 insulin pump with Control-IQ technology 1.5
Tandem Diabetes Care, Inc., Eli Lilly and Company, Jaeb Center for Health Research
Type 1 Diabetes
08/23
08/23
T1DES, NCT02734277: Type 1 Diabetes Extension Study

Recruiting
N/A
111
US
National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN)
Type 1 Diabetes Mellitus, T1DM, T1D
03/25
03/25
Wentworth, John
IAA, NCT05742243: Insulin and Abatacept in Recently-diagnosed Type 1 Diabetes

Active, not recruiting
2
62
RoW
Abatacept (CTLA4-Ig) and nasal insulin (Humulin R®), Abatacept and nasal insulin, Abatacept (CTLA4-Ig) and nasal placebo (0.9% sodium chloride), Abatacept and nasal placebo
Melbourne Health, National Health and Medical Research Council, Australia, Juvenile Diabetes Research Foundation
Type 1 Diabetes, Diabetes Mellitus, Type 1
02/26
02/27
NCT03929601: Rituximab-pvvr and Abatacept Vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes

Recruiting
2
74
US, RoW
Rituximab-pvvr, Ruxience, Abatacept, Orencia, Sterile Sodium Chloride, 0.9% Sodium Chloride Water for Injection
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH)
Type 1 Diabetes Mellitus
10/27
10/29
TN28, NCT04291703: STOP-T1D Low-Dose (ATG)

Active, not recruiting
2
101
US, RoW
Antithymocyte Globulin, Thymoglobulin, Placebo (for ATG)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Diabetes Mellitus, Type 1
12/28
12/29
Moore, Wayne
DETECT, NCT04786873 / 2018-001989-42: A Research Study of How Well Macimorelin Works to Find Out if Children Have a Lack of Growth Hormone and How Safe it is

Completed
3
101
Europe, US, RoW
Macimorelin, Macrilen, AEZS-130, Macimorelin GHST, Macimorelin test, Macrilen GHST, Macrilen test, Arginine, R-Gene 10, arginine test, arginine GHST, Clonidine, Catapressan 75, Clonidine test, Clonidine GHST
AEterna Zentaris, Novo Nordisk A/S
Growth Hormone Deficiency
06/24
06/24
NCT06449677: Bionic Pancreas in CFRD

Recruiting
3
150
US
iLet Bionic Pancreas System (BP), Usual Care (UC)
Jaeb Center for Health Research, Cystic Fibrosis Foundation, Massachusetts General Hospital, Beta Bionics, Inc.
Cystic Fibrosis-related Diabetes
11/25
03/26
NCT05743244: Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)

Recruiting
2
78
US
Abrocitinib 200 MG Oral Tablet, CIBINQO, Ritlecitinib, Placebo
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Pfizer
Diabetes Mellitus, Type 1
06/26
06/27
NCT03929601: Rituximab-pvvr and Abatacept Vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes

Recruiting
2
74
US, RoW
Rituximab-pvvr, Ruxience, Abatacept, Orencia, Sterile Sodium Chloride, 0.9% Sodium Chloride Water for Injection
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH)
Type 1 Diabetes Mellitus
10/27
10/29
TN28, NCT04291703: STOP-T1D Low-Dose (ATG)

Active, not recruiting
2
101
US, RoW
Antithymocyte Globulin, Thymoglobulin, Placebo (for ATG)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Diabetes Mellitus, Type 1
12/28
12/29
DESIGNATE, NCT05574335: Siplizumab in T1DM

Active, not recruiting
1/2
120
US
Siplizumab, TCD 601
National Institute of Allergy and Infectious Diseases (NIAID)
Type 1 Diabetes Mellitus
12/26
12/27
TOPPLE T1D, NCT04279613: A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041

Completed
1
47
US
NNC0361-0041, Placebo
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Novo Nordisk A/S
Type I Diabetes
08/23
04/24
T1DES, NCT02734277: Type 1 Diabetes Extension Study

Recruiting
N/A
111
US
National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN)
Type 1 Diabetes Mellitus, T1DM, T1D
03/25
03/25
NCT00097292: TrialNet Pathway to Prevention of T1D

Recruiting
N/A
75000
Europe, Canada, US, RoW
University of South Florida, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), American Diabetes Association, National Institute of Allergy and Infectious Diseases (NIAID), National Center for Research Resources (NCRR)
Diabetes Mellitus, Type 1
07/25
07/25
Resnick, Brittany
NCT03929601: Rituximab-pvvr and Abatacept Vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes

Recruiting
2
74
US, RoW
Rituximab-pvvr, Ruxience, Abatacept, Orencia, Sterile Sodium Chloride, 0.9% Sodium Chloride Water for Injection
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH)
Type 1 Diabetes Mellitus
10/27
10/29
Spall, Maria
NCT05378672: A Study to Inv. Safety, Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children <6 Years With T1D

Recruiting
3
8
US
Dasiglucagon, Zegalogue, ZP4207
Zealand Pharma, Novo Nordisk A/S
Hypoglycemia, Type 1 Diabetes
09/24
09/24
NCT05743244: Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)

Recruiting
2
78
US
Abrocitinib 200 MG Oral Tablet, CIBINQO, Ritlecitinib, Placebo
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Pfizer
Diabetes Mellitus, Type 1
06/26
06/27
NCT03929601: Rituximab-pvvr and Abatacept Vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes

Recruiting
2
74
US, RoW
Rituximab-pvvr, Ruxience, Abatacept, Orencia, Sterile Sodium Chloride, 0.9% Sodium Chloride Water for Injection
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH)
Type 1 Diabetes Mellitus
10/27
10/29
TN28, NCT04291703: STOP-T1D Low-Dose (ATG)

Active, not recruiting
2
101
US, RoW
Antithymocyte Globulin, Thymoglobulin, Placebo (for ATG)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Diabetes Mellitus, Type 1
12/28
12/29
TOPPLE T1D, NCT04279613: A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041

Completed
1
47
US
NNC0361-0041, Placebo
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Novo Nordisk A/S
Type I Diabetes
08/23
04/24
T1DES, NCT02734277: Type 1 Diabetes Extension Study

Recruiting
N/A
111
US
National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN)
Type 1 Diabetes Mellitus, T1DM, T1D
03/25
03/25
NCT00097292: TrialNet Pathway to Prevention of T1D

Recruiting
N/A
75000
Europe, Canada, US, RoW
University of South Florida, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), American Diabetes Association, National Institute of Allergy and Infectious Diseases (NIAID), National Center for Research Resources (NCRR)
Diabetes Mellitus, Type 1
07/25
07/25
Healy, Felicity
NCT03929601: Rituximab-pvvr and Abatacept Vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes

Recruiting
2
74
US, RoW
Rituximab-pvvr, Ruxience, Abatacept, Orencia, Sterile Sodium Chloride, 0.9% Sodium Chloride Water for Injection
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH)
Type 1 Diabetes Mellitus
10/27
10/29
TN28, NCT04291703: STOP-T1D Low-Dose (ATG)

Active, not recruiting
2
101
US, RoW
Antithymocyte Globulin, Thymoglobulin, Placebo (for ATG)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Diabetes Mellitus, Type 1
12/28
12/29
NCT00097292: TrialNet Pathway to Prevention of T1D

Recruiting
N/A
75000
Europe, Canada, US, RoW
University of South Florida, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), American Diabetes Association, National Institute of Allergy and Infectious Diseases (NIAID), National Center for Research Resources (NCRR)
Diabetes Mellitus, Type 1
07/25
07/25
Harding, Heather
INHALE-1, NCT04974528: Afrezza® Study in Pediatrics

Active, not recruiting
3
319
US
Afrezza, Technosphere Insulin, Rapid-acting Insulin Analog, insulin aspart, insulin lispro, insulin glulisine, Novolog®, Fiasp®, Humalog®, Admelog®, Apidra®, Basal Insulin, insulin glargine, insulin degludec, insulin detemir, Lantus®, Abasaglar®, Basaglar®, Semglee®, Toujeo®, Tresiba®, Levemir®
Mannkind Corporation, Jaeb Center for Health Research
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
10/24
05/25
NCT05743244: Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)

Recruiting
2
78
US
Abrocitinib 200 MG Oral Tablet, CIBINQO, Ritlecitinib, Placebo
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Pfizer
Diabetes Mellitus, Type 1
06/26
06/27
NCT03929601: Rituximab-pvvr and Abatacept Vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes

Recruiting
2
74
US, RoW
Rituximab-pvvr, Ruxience, Abatacept, Orencia, Sterile Sodium Chloride, 0.9% Sodium Chloride Water for Injection
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH)
Type 1 Diabetes Mellitus
10/27
10/29
TADPOL, NCT05594563: TArgeting Type 1 Diabetes Using POLyamines

Recruiting
2
70
US
DFMO, Difluoromethylornithine, Placebo
Emily K. Sims, Juvenile Diabetes Research Foundation, Cancer Prevention Pharmaceuticals, Inc.
Type 1 Diabetes
12/27
12/27
TN28, NCT04291703: STOP-T1D Low-Dose (ATG)

Active, not recruiting
2
101
US, RoW
Antithymocyte Globulin, Thymoglobulin, Placebo (for ATG)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Diabetes Mellitus, Type 1
12/28
12/29
Johnson, Carter
INHALE-1, NCT04974528: Afrezza® Study in Pediatrics

Active, not recruiting
3
319
US
Afrezza, Technosphere Insulin, Rapid-acting Insulin Analog, insulin aspart, insulin lispro, insulin glulisine, Novolog®, Fiasp®, Humalog®, Admelog®, Apidra®, Basal Insulin, insulin glargine, insulin degludec, insulin detemir, Lantus®, Abasaglar®, Basaglar®, Semglee®, Toujeo®, Tresiba®, Levemir®
Mannkind Corporation, Jaeb Center for Health Research
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
10/24
05/25
TN28, NCT04291703: STOP-T1D Low-Dose (ATG)

Active, not recruiting
2
101
US, RoW
Antithymocyte Globulin, Thymoglobulin, Placebo (for ATG)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Diabetes Mellitus, Type 1
12/28
12/29

Download Options